Continuing Medical Education
Physicians
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex, LLC designates this educational activity for a maximum 17.75 of AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physician Assistants
AAPA accepts certificates of participation for educational activities certified for Category I credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 17.75 hours of Category I credit for completing this program.
Nurses
This continuing nursing education activity was approved by the Oncology Nursing Society, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
Target Audience
This educational activity is specifically designed for hematologists, medical oncologists, transplant oncologists, radiation oncologists and other physicians, physicians-in-training, and healthcare professionals (oncology nurses, oncology pharmacy specialists) involved in and/or interested in lymphoma, myeloma and related plasma cell disorders and their management.
Learning Objectives
After attending this conference, participants should be able to:
- Summarize clinical trial data regarding at least 4 novel or emerging agents being developed for treatment of relapsed/refractory myeloma
- Relate the latest information on how a patient’s eligibility for stem cell transplant affects selection of first-line treatments in myeloma
- Restate at least one argument for stem cell transplant as initial treatment and at least one argument for waiting until first relapse
- Use the latest information from basic science, transplantation, and clinical research to reduce adverse events and improve outcomes in myeloma patients
- Identify at least 1 biochemical signaling pathway that shows therapeutic promise in CLL
- Compare and contrast competing standards of care for newly diagnosed and relapsed CLL patients
- Recall the most current arguments for and against using prognostic factors to make treatment decisions in CLL
- Synthesize the latest information from basic research, laboratory tests, and clinical research to improve outcomes for patients with CLL
- Comment on the state of basic science regarding lymphomagenesis
- Judge recent attempts to establish a new standard of care for frontline therapy of patients with follicular lymphoma
- Use the latest clinical trial data to infer whether it is possible to improve frontline therapy in aggressive lymphoma
- Extrapolate upon the latest basic science and clinical research data to extend professional competence when managing patients with NHL